Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. März 2021 07:00 ET | Quelle: Athira Pharma, Inc.

Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference

BOTHELL, Wash., March 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
08. März 2021 07:00 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors

BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
02. März 2021 07:00 ET | Quelle: Athira Pharma, Inc.

Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
10. Februar 2021 16:05 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Exercise of Underwriters’ Option to Purchase Additional Shares

BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
20. Januar 2021 19:35 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
19. Januar 2021 07:59 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Proposed Public Offering of Common Stock

BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
07. Januar 2021 07:30 ET | Quelle: Athira Pharma, Inc.

Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
14. Dezember 2020 07:30 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors

SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
08. Dezember 2020 07:30 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
01. Dezember 2020 07:30 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease

SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

Vorherige Seite

Nächste Seite